Elbow stiffness
Conditions
Interventions
Intravenous group:Intravenous (15mg/kg) use tranexamic acid in 100ml normal saline, topical normal saline 10ml
Topical group:Intravenous use 100ml normal saline, topical tranexamic acid 1000mg(10ml)
Combined group:Intravenous (15mg/kg) use tranexamic acid in 100ml normal saline, topical tranexamic acid 1000mg(10ml)
Sponsors
Beijing Jishuitan Hospital, Orthopaedics Trauma Department
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: All elbow stiffness patients undergoing elbow release during study period.
Exclusion criteria
Exclusion criteria: Hb less than 110g/L; Contraindication or allergy to tranexamic acid (e.g previous arterial or venous thrombosis, renal dysfunction( glomerular filtration rate<30), previous seizure); Acquired disturbances of color vision; Acute myocardial infarction in 6 months; Cerebrovascular diseases in 6 months( e.g cerebral infarction, cerebral hemorrhage; DVT or PE or Arterial stent surgery in one year; Thrombophilia( e.g end stage of malignancy, Disseminated intravascular coagulation, severe hyperlipidemia, glucocorticoid replacement therapy); Hypercoagulation status or hemophilia; Using warfarin, heparin of estrogen in perioperative period; Skin defect or history of skin graft; Injury of neurovascular structure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hidden blood loss; | — |
Secondary
| Measure | Time frame |
|---|---|
| Drainage keeping time;Drainage amount;Mean blood transfusion;Mean blood transfusion rate;Range of motion;Surgery related complication; | — |
Countries
China
Contacts
Public ContactJiang Xieyuan
Beijing Jishuitan Hospital
Outcome results
None listed